Ballew Advisors’s GSK GSK Stock Holding History

Ballew Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$524K	Buy	9,761 +1	+0%	+$53	0.27%	70
2026 Q1	$570K	Sell	9,760 -4	-0%	-$217	0.32%	64
2025 Q4	$487K	Buy	9,764 +2	+0%	+$93	0.27%	69
2025 Q3	$431K	Buy	9,762 +3	+0%	+$117	0.24%	77
2025 Q2	$373K	Buy	9,759 +1	+0%	+$38	0.22%	78
2025 Q1	$338K	Hold	9,758	–	–	0.23%	80
2024 Q4	$319K	Sell	9,758 -372	-4%	-$13.4K	0.2%	83
2024 Q3	$408K	Hold	10,130	–	–	0.27%	71
2024 Q2	$392K	Buy	10,130 +29	+0.3%	+$1.22K	0.26%	75
2024 Q1	$411K	Hold	10,101	–	–	0.28%	75
2023 Q4	$403K	Buy	10,101 +9	+0.1%	+$323	0.3%	73
2023 Q3	$364K	Buy	10,092 +5	+0%	+$177	0.3%	73
2023 Q2	$344K	Hold	10,087	–	–	0.25%	78
2023 Q1	$358K	Buy	10,087 +8	+0.1%	+$280	0.26%	77
2022 Q4	$354K	Hold	10,079	–	–	0.27%	71
2022 Q3	$304K	Buy	10,079 +5	+0%	+$190	0.27%	73
2022 Q2	$506K	Buy	10,074 +4	+0%	+$221	0.46%	52
2022 Q1	$590K	Buy	10,070 +352	+4%	+$19.1K	0.45%	52
2021 Q4	$552K	Buy	9,718 +1	+0%	+$52	0.38%	65
2021 Q3	$470K	Hold	9,717	–	–	0.35%	66
2021 Q2	$492K	Sell	9,717 -9,710	-50%	-$467K	0.34%	68
2021 Q1	$870K	Buy	19,427 +9,715	+100%	+$441K	0.32%	69
2020 Q4	$460K	Buy	9,712 +112	+1%	+$5.14K	0.35%	62
2020 Q3	$452K	Hold	9,600	–	–	0.38%	53
2020 Q2	$485K	Hold	9,600	–	–	0.48%	43
2020 Q1	$455K	Hold	9,600	–	–	0.51%	35
2019 Q4	$560K	Hold	9,600	–	–	0.48%	44
2019 Q3	$503K	Hold	9,600	–	–	0.46%	49
2019 Q2	$491K	Hold	9,600	–	–	0.45%	51
2019 Q1	$486K	Hold	9,600	–	–	0.45%	49
2018 Q4	$493K	Hold	9,600	–	–	0.46%	47
2018 Q3	$472K	Hold	9,600	–	–	0.43%	50
2018 Q2	$484K	Hold	9,600	–	–	0.55%	43
2018 Q1	$469K	Hold	9,600	–	–	0.41%	53
2017 Q4	$426K	Buy	+9,600	New	+$443K	0.42%	52

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Ballew Advisors's GSK Position: Q2 2026 in Review

Ballew Advisors increased its GSK (GSK) stake by 0.01% in Q2 2026, buying an estimated $53 and bringing the position to 9,761 shares worth $524K. The position accounts for 0.27% of the portfolio, ranked #70.

Ballew Advisors first reported a position in GSK in Q4 2017 and has held it in 35 quarters since. The position peaked at $870K in Q1 2021. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Ballew Advisors held 9,761 shares of GSK worth $524K as of Q2 2026.
Ballew Advisors bought 1 GSK share in Q2 2026, an estimated $53.
GSK made up 0.27% of Ballew Advisors's portfolio in Q2 2026, its #70 holding.
Ballew Advisors first reported a position in GSK in Q4 2017 and has held it in 35 quarters since.
Ballew Advisors's GSK position peaked at $870K in Q1 2021.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Ballew Advisors's 13F filing for Q2 2026, filed 7 Jul 2026.